Navigation Links
Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C
Date:5/4/2010

eplicon studies, (4) and laboratory studies indicate that it does not induce viral mutations that confer drug resistance. (5)  Nitazoxanide is synergistic with interferon and direct acting antivirals in replicon studies. (4,6)  In patients with chronic hepatitis C, the addition of nitazoxanide has not resulted in an increase in the toxicity associated with peginterferon and ribavirin.  Studies in patients with genotype 4 chronic hepatitis C suggest that nitazoxanide may be used to replace ribavirin. (1,2)  The AIDS Clinical Trials Group (ACTG) in the United States is studying nitazoxanide plus peginterferon and ribavirin for treating chronic hepatitis C in patients coinfected with HIV.

"Patients with chronic hepatitis C are diverse in many respects with patient and virus characteristics that affect treatment outcomes (HCV genotype, viral load, stage of liver disease, IL28B genotype, race, body weight, coinfection with HIV or hepatitis B virus, and ability to tolerate treatment)," said Emmet B. Keeffe, Chief Medical Officer of Romark Laboratories.  "The trend in therapy of chronic hepatitis C has been toward individualized therapy with combinations of antiviral drugs.  There is a need for a new class of safe drugs with novel mechanism that can be used in combination with current standard therapy or with other new classes of drugs to improve treatment outcomes.  We believe nitazoxanide can play an important role in these combinations."

About Hepatitis C

Hepatitis C is a blood-borne infectious disease that is caused by the hepatitis C virus (HCV). It is the most common cause of chronic hepatitis in the U.S. and may eventually lead to cirrhosis, liver cancer and liver failure. The disease is transmitted by contact with HCV-infected blood.  A large majority of those i
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
3. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
5. Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
6. Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... NESS ZIONA, Israel , September ... BVXV, TASE: BVXV) today announced the intent of the National ... U.S. National Institutes of Health (NIH) within the Department of ... 2 trial to be held in the United ... examine the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing ... high-risk surgeries. From vital sign monitoring in ICU to 3D skull printing analysis ... to make real-time clinical decisions with simultaneous access to high precision medical images ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's new $100,000 waste ... energy process and continue to contribute to the sustainability of our natural resources. ... Energy process has been operating at their Mexico facility, Recicladora Temarry, for the ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... science research, today unveiled Genedata Screener ® version 13.0 at ELRIG Drug ... brings to market a rich set of new capabilities. Screener now supports High ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... Total Hemoglobin Adhesive ... ... Masimo (Nasdaq:,MASI), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion-and-Low-Perfusion pulse ... (SpHb(TM)) and,oxygen content (SpOC(TM)) monitors, Radical-7 and Rad-87. Masimo also,announced ...
... Inc.,(OTC Bulletin Board: MODG), a biopharmaceutical company applying ... approved,therapeutic proteins, today announced that President Shai Novik ... Conference at 2:00 PM EDT,on September 24, 2008., ... will be webcast live.,It can be accessed at ...
... Barriers and Paves Way ... for Affordable and Efficient Approach, KAKAMEGA, Kenya, Sept. 15 ... was launched today in the Western,Kenyan district of Kakamega in ... care package consisting of a,PermaNet(R) long-lasting insecticide-treated bed net, a ...
Cached Biology Technology:Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors 2Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors 3Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors 4Integrated Prevention Demonstration Campaign Launched in Western Kenya to Fight HIV, Malaria and Diarrhoeal Disease 2Integrated Prevention Demonstration Campaign Launched in Western Kenya to Fight HIV, Malaria and Diarrhoeal Disease 3
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
(Date:8/18/2015)... 2015  Navitas today announced that it ... Submission Content Management webinar scheduled on August ... to the Implementation of Regulatory Submission Standards ... industry, vendors, health authorities, consultants and the ... a standard method of implementing electronic submission ...
(Date:8/12/2015)... CORAL SPRINGS, Florida , August 12, 2015 /PRNewswire/ ... globally, the pace of mobile payment innovation and advanced ... continues to replace the way consumers rely on using ... forges ahead with reinventing the future for payment services ... Inc. (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... an international public-private consortium to build the most detailed ... completion of three pilot projects and the deposition of ... for use by the research community. In addition, work ... public database containing information from the genomes of 2,500 ...
... diet rich in natural antioxidants improves insulin sensitivity in ... insulin-sensitizing drug metformin, a preliminary study from Italy finds. ... Society,s 92nd Annual Meeting in San Diego. "The ... revealed for the first time one of their biological ...
... PHILADELPHIA - A team of bioengineers from the University ... a computer neural network model to accurately predict how ... a heart attack or stroke. Using an automated, ... of different combinations of biological stimuli like those experienced ...
Cached Biology News:Freely available data supporting next generation of human genetic research 2Freely available data supporting next generation of human genetic research 3Freely available data supporting next generation of human genetic research 4Freely available data supporting next generation of human genetic research 5Freely available data supporting next generation of human genetic research 6Well-defined quantity of antioxidants in diet can improve insulin resistance 2Penn bioengineers create simulator to test blood platelets in virtual heart attacks 2Penn bioengineers create simulator to test blood platelets in virtual heart attacks 3
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, detection range 0.04% to 4%. Procedure: 30 min....
... Mouse monoclonal [APS 26] to Presenilin ... an inherited form of the disease carry ... or the amyloid precursor protein (APP). These ... the longer form of amyloid-beta (main component ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
Biology Products: